Tofacitinib for the Treatment of Primary Localized Cutaneous Amyloidosis
The Journal of Dermatology · 2025
DOI: 10.1111/1346-8138.17869 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Qin-Xiao Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Pyrimidines, Piperidines, Protein Kinase Inhibitors, Amyloidosis, Familial. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Primary localized cutaneous amyloidosis (PLCA) is a chronic skin disorder that can cause persistent pruritus and cosmetic disfigurement and remains challenging to treat. Tofacitinib, an oral Janus kinase inhibitor, has shown potential therapeutic benefits for PLCA. We conducted a retrospective study of 24 patients with PLCA treated with tofacitinib (10 mg/day) at our dermatology clinic. Disease severity was assessed using body surface area (BSA), Peak Pruritus Numerical Rating Scale (PP‐NRS), and Investigator Global Assessment (IGA) scores. Significant improvements were observed in BSA ( p < 0.05), PP‐NRS ( p < 0.001), and IGA ( p < 0.01) at week 4. Treatment was well tolerated, with no serious adverse events leading to discontinuation. The findings of this study suggest that tofacitinib could be an appealing approach for treating PLCA. Further large‐scale, randomized controlled trials are necessary to confirm its long‐term efficacy and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
ORCID-Profile: Sheng Fang
Zitieren
APA
Wang, Q. X., He, H. Y., Niu, Y. L., & Fang, S. (2025). Tofacitinib for the Treatment of Primary Localized Cutaneous Amyloidosis. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17869
Vancouver
Wang QX, He HY, Niu YL, Fang S. Tofacitinib for the Treatment of Primary Localized Cutaneous Amyloidosis. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17869
BibTeX
@article{Wang2025,
author = {Wang, Qin-Xiao and He, Hai-Yang and Niu, Ying-Luo and Fang, Sheng},
title = {Tofacitinib for the Treatment of Primary Localized Cutaneous Amyloidosis},
journal = {The Journal of Dermatology},
year = {2025},
doi = {10.1111/1346-8138.17869}
}
EUVIMED